Astellas, Zydus Cadila Settle Patent Suit on Xtandi Cancer Drug

Astellas, Pfizer’s Medivation and the University of California have agreed to drop a lawsuit accusing Zydus Cadila of infringing three Xtandi patents with its proposed generic version of the prostate-cancer drug.

• Zydus’s counterclaims also were dropped, according to an agreement approved May 8 in federal court in Wilmington, Delaware
• Details of the settlement weren’t released but it removes the final defendant from the consolidated case, according to the electronic docket
• Astellas reported Xtandi sales of 333.1 billion yen ($3.02 billion) in the 12 months ended March 31, up by 13.2% from the same period a year earlier, Astellas said April ...